Ansaid

Pain, Chronic Pain, Postoperative Pain + 14 more
Treatment
5 FDA approvals
20 Active Studies for Ansaid

What is Ansaid

FlurbiprofenThe Generic name of this drug
Treatment SummaryFlurbiprofen is a type of medication used to reduce inflammation, fever, and pain. It is taken orally to treat rheumatoid arthritis, osteoarthritis and anklylosing spondylitis, or applied topically to the eyes prior to surgery. Flurbiprofen is similar to other drugs like ibuprofen, fenoprofen, and ketoprofen in terms of structure and effect.
Ocufenis the brand name
Ansaid Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ocufen
Flurbiprofen
1987
34

Approved as Treatment by the FDA

Flurbiprofen, also called Ocufen, is approved by the FDA for 5 uses including Menstrual Distress (Dysmenorrhea) and Ankylosing Spondylitis (AS) .
Menstrual Distress (Dysmenorrhea)
Ankylosing Spondylitis (AS)
Ankylosing Spondylitis
Pain
Dysmenorrhea

Effectiveness

How Ansaid Affects PatientsFlurbiprofen is a type of nonsteroidal anti-inflammatory drug (NSAID) similar to fenoprofen, ibuprofen, and ketoprofen. It works to reduce inflammation, pain, and fever. This drug is composed of two different forms (left and right-hand versions) known as enantiomers. The left-hand version is believed to be the one that provides most of the anti-inflammatory effects, while both versions may help with pain relief.
How Ansaid works in the bodyFlurbiprofen is a type of non-steroidal anti-inflammatory drug (NSAIA) which works by blocking an enzyme that turns fatty acids into molecules that cause inflammation. This stops the production of these inflammatory molecules and helps to reduce pain, swelling and fever. Flurbiprofen is especially powerful at blocking this enzyme, making it one of the most effective NSAIAs.

When to interrupt dosage

The measure of Ansaid is reliant upon the distinguished ailment, including Postoperative Pain, Menstrual Distress (Dysmenorrhea) and Back. The total of dosage varies, contingent upon the technique of delivery (e.g. Tablet, film coated or Liquid - Ophthalmic) specified in the table underneath.
Condition
Dosage
Administration
Pain
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Chronic Pain
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Postoperative Pain
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Rheumatoid Arthritis
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Rheumatoid Arthritis
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Pain
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Neurodegenerative Diseases
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Dysmenorrhea
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Back
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Spasm
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Lumbar Region
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Osteoarthritis
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Ankylosing Spondylitis
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Epilepsy, Post-Traumatic
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Chronic Back Pain
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Wounds and Injuries
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic
Spasm
0.3 mg/mL, , 100.0 mg, 0.242 mg/mL, 3.3 mg, 50.0 mg, 200.0 mg, 0.03 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Topical, Patch, Patch - Topical, Tablet, Tablet - Oral, Capsule, extended release - Oral, Capsule, extended release, Liquid, Liquid - Ophthalmic

Warnings

There are 20 known major drug interactions with Ansaid.
Common Ansaid Drug Interactions
Drug Name
Risk Level
Description
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Flurbiprofen.
Belinostat
Major
The metabolism of Belinostat can be decreased when combined with Flurbiprofen.
Binimetinib
Major
The metabolism of Binimetinib can be decreased when combined with Flurbiprofen.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Flurbiprofen.
Etoposide
Major
The metabolism of Etoposide can be decreased when combined with Flurbiprofen.
Ansaid Toxicity & Overdose RiskThe toxic dose of flurbiprofen in dogs is 10mg/kg when taken orally. It has been linked to an increased risk of heart attack, stroke, high blood pressure, fluid retention and swelling, and stomach irritation. It can also cause kidney damage, allergic reactions, abdominal pain, constipation, diarrhea, indigestion, gas, vomiting, anemia, dizziness, headache, prolonged bleeding, itching, rashes, and ringing in the ears. Rarely, allergic reactions may occur.

Ansaid Novel Uses: Which Conditions Have a Clinical Trial Featuring Ansaid?

293 active studies are being conducted to assess the potential of Ansaid to alleviate symptoms associated with Osteoarthritis (OA), Rheumatoid Arthritis and Pain.
Condition
Clinical Trials
Trial Phases
Chronic Pain
129 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1
Spasm
0 Actively Recruiting
Rheumatoid Arthritis
8 Actively Recruiting
Not Applicable, Phase 4, Phase 2
Back
0 Actively Recruiting
Postoperative Pain
18 Actively Recruiting
Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable
Pain
0 Actively Recruiting
Neurodegenerative Diseases
4 Actively Recruiting
Phase 2, Phase 3, Not Applicable
Dysmenorrhea
1 Actively Recruiting
Not Applicable
Spasm
0 Actively Recruiting
Pain
0 Actively Recruiting
Wounds and Injuries
7 Actively Recruiting
Not Applicable, Phase 3
Ankylosing Spondylitis
3 Actively Recruiting
Phase 3, Not Applicable
Chronic Back Pain
5 Actively Recruiting
Not Applicable
Lumbar Region
1 Actively Recruiting
Not Applicable
Epilepsy, Post-Traumatic
0 Actively Recruiting
Rheumatoid Arthritis
53 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1
Osteoarthritis
0 Actively Recruiting

Ansaid Reviews: What are patients saying about Ansaid?

5Patient Review
3/3/2010
Ansaid for Joint Damage causing Pain and Loss of Function
I have osteoarthritis in my knee, which was exacerbated by spinal fusion surgery. I tried this medication in conjunction with Synevisc and after taking it for a few months, I feel much better. I would recommend this to others who are struggling with similar issues.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ansaid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Ansaid good for toothache?

"It is used to relieve pain in conditions like headache, mild migraines, muscle pain, joint pain, tooth pain, menstrual pain, ankylosing spondylitis, osteoarthritis and rheumatoid arthritis."

Answered by AI

What is Ancid used for?

"Ancid 150mg Tablet is a medicine that reduces the amount of acid your stomach makes. It can be used to treat and prevent heartburn as well as indigestion and other symptoms caused by too much acid in the stomach. It can also be used to treat and prevent stomach ulcers, reflux disease, and some rarer conditions."

Answered by AI

What is Ansaid tablets used for?

"Ansaid is a prescription medicine used to treat the symptoms of Rheumatoid arthritis and Osteoarthritis. Ansaid may be used alone or with other medications."

Answered by AI

Is Ansaid the same as ibuprofen?

"Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body. Flurbiprofen is similar to other NSAIDs such as ibuprofen (Motrin or Advil), naproxen (Naprosyn), and others."

Answered by AI

Clinical Trials for Ansaid

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Our Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What We Think: We believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What We're Doing: We will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing we'll look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. We'll also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: We've already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. We've also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, we need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.
Phase 4
Waitlist Available
Sunnybrook Health Sciences Centre (+4 Sites)
Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Have you considered Ansaid clinical trials? We made a collection of clinical trials featuring Ansaid, we think they might fit your search criteria.Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

Lidocaine Infusions for Postoperative Pain

18+
All Sexes
Nashville, TN
The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major abdominal surgery. The main questions the trial aims to answer are: The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS). The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).
Phase 4
Waitlist Available
Vanderbilt University Medical CenterDanial Shams, MD
Image of Baylor College of Medicine/Texas Children's Hospital in Austin, United States.

Guided Imagery Therapy for Abdominal Pain

7 - 12
All Sexes
Austin, TX
Chronic abdominal pain is common among children, and the majority of cases are attributed to functional abdominal pain disorders. One approach to treating these disorders is by using psychological therapies. This clinical trial aims to see how well pre-recorded guided imagery therapy sessions help children's abdominal pain when delivered via a mobile application (app) on a smartphone or tablet. Participants will complete a baseline abdominal pain and stooling diary to determine eligibility, as well as other surveys. Eligible participants will be given access to the guided imagery therapy mobile application. This intervention asks participants to listen to a 10- to 15-minute GIT session 5 out of 7 days per week for 8 weeks, in addition to their usual care for their abdominal pain. Then, participants will complete another abdominal pain and stooling diary, along with other psychometric surveys, at the end of this intervention period. Participants will also collect another diary and surveys 3 months post-treatment.
Waitlist Available
Has No Placebo
Baylor College of Medicine/Texas Children's Hospital (+1 Sites)
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Have you considered Ansaid clinical trials? We made a collection of clinical trials featuring Ansaid, we think they might fit your search criteria.Go to Trials
Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.
Waitlist Available
Has No Placebo
Humana Healthcare Research, Inc. (+1 Sites)
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Image of UI Health Care Center for Advanced Reproductive Care in Iowa City, United States.

Ketorolac for Infertility Treatment

18 - 37
Female
Iowa City, IA
Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy. However, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle). Despite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research. This study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would. Primary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia. Secondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w/in 24 hours for pain/bleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.
Phase 4
Recruiting
UI Health Care Center for Advanced Reproductive Care
Have you considered Ansaid clinical trials? We made a collection of clinical trials featuring Ansaid, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security